Robinson Chandler: insider trades.
Robinson Chandler reported 8 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($2.6M), across 1 company.
- Transactions
- 8
- Purchases (P)
- 0
- Sales (S)
- 4
- Companies
- 1
- Name as filed
- Robinson Chandler
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Monopar Therapeutics (MNPR) | Director, Officer · Chief Executive Officer | 8 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-24 | Monopar Therapeutics | S | 600 | $89.79 | 99,267 | Form 4 |
| 2026-09-24 | Monopar Therapeutics | S | 8,368 | $88.97 | 99,867 | Form 4 |
| 2026-09-24 | Monopar Therapeutics | S | 9,638 | $87.96 | 108,235 | Form 4 |
| 2026-09-24 | Monopar Therapeutics | S | 10,450 | $87.15 | 117,873 | Form 4 |
| 2026-09-24 | Monopar Therapeutics | M | 14,056 | $30 | 113,323 | Form 4 |
| 2026-09-24 | Monopar Therapeutics | M | 15,000 | $14 | 128,323 | Form 4 |
| 2026-06-30 | Monopar Therapeutics | M | 12,873 | — | 103,351 | Form 4 |
| 2026-06-30 | Monopar Therapeutics | F | 4,084 | $92.59 | 99,267 | Form 4 |
Questions
What stock did Robinson Chandler buy or sell?
Robinson Chandler reported 8 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($2.6M), across 1 company.
Is Robinson Chandler the same person as other filers with this name?
This page covers SEC CIK 1727334 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/robinson-chandler-1727334.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.